Our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. We have two clinical programs focused on products for rare, chronic respiratory diseases.
Cooperation possibilities
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor and EnBiotix, which merged in December 2021.
- https://www.spexisbio.com/
- +41 61 567 16 00
- info@spexisbio.com
